Ukr.Biochem.J. 2022; Volume 94, Issue 3, May-Jun, pp. 92-98

doi: https://doi.org/10.15407/ubj94.03.092

New formulation and activity of rhenium-platinum antitumor system

29.09.2022   Uncategorized   No comments

N. I. Shtemenko1,2*, D. E. Kytova1, O. V. Berzenina1,
O. I. Hrabovska1,3, A. V. Shtemenko1

1Ukrainian State University of Chemical Technology, Dnipro, Ukraine;
2Oles Honchar Dnipro National University, Ukraine;
3SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine;
*e-mail: n.shtemenko@ukr.net

Received: 16 November 2021; Revised: 10 January 2022; Accepted: 29 September 2022; Available on-line: October 2022

Two-component Rhenium-Platinum system (Re-Pt system) is based on administration of a cluster dirhenium(III) compound and cisplatin to tumor bearing animals followed by a significant antitumor effect and decreased toxic effect of cisplatin on normal cells. The aim of this work was to obtain solid lipid nanoparticles (SLN) from surface lipids (waxes) of Chelidonium majus L. (Papaveraceae) leaves and to estimate whether capsulation of dirhenium(III) as a component of the Re-Pt system into SLN will affect its antitumor activity and red blood cells (RBC) morphology in a rat model of Guerin’s carcinoma growth. Fourier-transform infrared spectroscopy, gas-liquid chromatography, microscopy, light scattering were used in the research. Solid lipid nanoparticles were obtained, characterized, loaded with cluster dirhenium(III) and being introduced together with cisplatin to rats with Guerin’s carcinoma resulted in RBC morphology preservation and a significant decrease in tumor weight. It was concluded that the lipid coating of the rhenium cluster compound did not reduce the antitumor effect of the Re-Pt system and protected RBC from toxic cisplatin influence­. A new formulation of the Re-Pt system is proposed.

Keywords: , , , ,

References:

  1. Shtemenko N, Collery P, Shtemenko A. Dichlorotetra-mu-Isobutyratodirhenium(III): enhancement of cisplatin action and RBC-stabilizing properties. Anticancer Res. 2007;27(4B):2487-2492. PubMed
  2. Shtemenko AV, Shtemenko NI. Rhenium–platinum antitumor systems. Ukr Biochem J. 2017;89(2):5–30. CrossRef
  3. Li Z, Shtemenko NI, Yegorova DY, Babiy SO, Brown AJ, Yang T, Shtemenko AV, Dunbar KR. Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity. J Liposome Res. 2015;25(1):78-87. PubMed, CrossRef
  4. Golichenko A, Shtemenko A. Hydrolysis of rhenium(III) cluster compounds. Ukr Chem J. 2019;85(3):27-34. CrossRef
  5. Bayón-Cordero L, Alkorta I, Arana L. Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs. Nanomaterials (Basel). 2019;9(3):474. PubMed, PubMedCentral, CrossRef
  6. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid Nanoparticles as Carriers for Bioactive Delivery. Front Chem. 2021;9:580118. PubMed, PubMedCentral, CrossRef
  7. Colombo ML, Bosisio E. Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol Res. 1996;33(2):127-134. PubMed, CrossRef
  8. Capistrano I R, Wouters A, Lardon F, Gravekamp C, Apers S, Pieters L. In vitro and in vivo investigations on the antitumour activity of Chelidonium majus. Phytomedicine. 2015;22(14):1279-1287. PubMed, CrossRef
  9. Noureini SK, Esmaeili H, Abachi F, Khiali S, Islam B, Kuta M, Saboury AA, Hoffmann M, Sponer J, Parkinson G, Haider S. Selectivity of major isoquinoline alkaloids from Chelidonium majus towards telomeric G-quadruplex: A study using a transition-FRET (t-FRET) assay. Biochim Biophys Acta Gen Subj. 2017;1861(8):2020-2030. PubMed, CrossRef
  10. Zielińska S, Wójciak-Kosior M, Dziągwa-Becker M, Gleńsk M, Sowa I, Fijałkowski K, Rurańska-Smutnicka D, Matkowski A, Junka A. The Activity of Isoquinoline Alkaloids and Extracts from Chelidonium majus against Pathogenic Bacteria and Candida sp. Toxins (Basel). 2019;11(7):406. PubMed, PubMedCentral, CrossRef
  11. Shtemenko AV, Chifotides HT, Yegorova DE, Shtemenko NI, Dunbar KR. Synthesis and X-ray crystal structure of the dirhenium complex Re2(i-C3H7COO)4Cl2 and its interactions with the DNA purine nucleobases. J Inorg Biochem. 2015;153:114-120. PubMed, CrossRef
  12. Berzenina OV, Kytova DE, Shtemenko AV, Shtemenko NI. Surface lipids of kalanhoe as a material for nanoparticles preparation. Vopr Khim Khim Tekhnol. 2021;(3):57-63. CrossRef
  13. Shamelashvili KL, Shtemenko NI, Leus LV, Babiy SO, Shtemenko OV. Changes in oxidative stress intensity in blood of tumor-bearing rats following different modes of administration of rhenium-platinum system. Ukr Biochem J. 2016;88(4):29-39. PubMed, CrossRef
  14. Shtemenko OV, Zeleniuk MA, Shtemenko NI, Verbyts’ka IaS.Spectrophotometric study of the interaction between rhenium complexes and phosphatidylcholine during liposome formation. Ukr Biokhim Zhurn. 2002;74(6):91-96. (In Ukrainian). PubMed
  15. Rosiaux Y, Jannin V, Hughes S, Marchaud D. Solid lipid excipients – matrix agents for sustained drug delivery. J Control Release. 2014;188:18-30. PubMed, CrossRef
  16. Soleimanian Y, Goli SAH, Shirvani A, Elmizadeh A, Marangoni AG. Wax-based delivery systems: Preparation, characterization, and food applications. Compr Rev Food Sci Food Saf. 2020;19(6):2994-3030. PubMed, CrossRef
  17. El-Menshawe SF, Sayed OM, Abou Taleb HA, Saweris MA, Zaher DM, Omar HA. The use of new quinazolinone derivative and doxorubicin loaded solid lipid nanoparticles in reversing drug resistance in experimental cancer cell lines: A systematic study. J Drug Deliv Sci Technol. 2020;56:101569. CrossRef
  18. Valdivia L, García-Hevia L, Bañobre-López M, Gallo J, Valiente R, López Fanarraga M. Solid Lipid Particles for Lung Metastasis Treatment.  Pharmaceutics. 2021;13(1):93. PubMed, PubMedCentral,CrossRef
  19. Voronkova YS, Babiy SO, Ivans’ka LV, Shtemenko OV, Shtemenko NI. Antioxidant properties of cluster rhenium compounds and their influence of erythropoiesis of rats with Guerin carcinoma. Ukr Biochem J. 2015;87(1):99-108. (In Ukrainian). PubMed, CrossRef
  20. Slipkan AV, Kharlova MI, Shtemenko AV, Shtemenko NI. Fluorescent nanoparticles loaded with rhenium compounds and their biocompatibility with erythrocytes. Odesa Nat Univ Herald Chem. 2019;25(2(70)):29-38. CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.